Video
Dr. Kim and Dr. Kapur on the “disconnect” between exploring and receiving therapy for OAB
Author(s):
“I think there's a disconnect between the patients saying they're interested in these therapies, and the patients that actually go on to [receive] them,” says Jason Kim, MD.
Video Player is loading.
In this video, Anjali Kapur, MD, and Jason Kim, MD, discuss the takeaways of the study, “Patient preference of third line therapy for overactive bladder,” which will be presented at the Society of Women in Urology Annual Clinical Mentoring Conference. Kapur is a PGY-4 resident and Kim is an associate professor of urology, director of the Women’s Pelvic Health and Continence Center, and urology residency program director at Stony Brook Medicine in East Setauket, New York.
Related Videos
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Study results affirm effectiveness of evolving prostate cancer therapies
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Expert discusses genitourinary syndrome of menopause guidelines
Related Content
